RT @CMAJ: Although PCSK9 inhibitors are effective in improving cardiovascular outcomes, their use is limited by cost. Five things to know:…
RT @CMAJ: Although PCSK9 inhibitors are effective in improving cardiovascular outcomes, their use is limited by cost. Five things to know:…
RT @CMAJ: Although PCSK9 inhibitors are effective in improving cardiovascular outcomes, their use is limited by cost. Five things to know:…
And also.... "long-term safety data lacking"
Although PCSK9 inhibitors are effective in improving cardiovascular outcomes, their use is limited by cost. Five things to know: https://t.co/585ryOTSld @Pete_Wu @Derek_Leong_RPh #cardiovascular #healtheconomics https://t.co/3rt6L26TTW
RT @FarmaMadridAP: (CMAJ) 5 aspectos a conocer sobre los inhibidores de PCSK9 (evolocumab y alirocumab) https://t.co/bvLBcEfooA https://t.c…
RT @CMAJ: Although PCSK9 inhibitors are effective in improving cardiovascular outcomes, their use is limited by cost. Five things to know:…
Although PCSK9 inhibitors are effective in improving cardiovascular outcomes, their use is limited by cost. Five things to know: https://t.co/XWvh6A7BNu @Pete_Wu @Derek_Leong_R #cardiovascular #healtheconomics https://t.co/WkVZa9DH6R
Congrats @Derek_Leong_RPh on this informative publication on PCSK9 Inhibitors!!
RT @FarmaMadridAP: (CMAJ) 5 aspectos a conocer sobre los inhibidores de PCSK9 (evolocumab y alirocumab) https://t.co/bvLBcEfooA https://t.c…
RT @FarmaMadridAP: (CMAJ) 5 aspectos a conocer sobre los inhibidores de PCSK9 (evolocumab y alirocumab) https://t.co/bvLBcEfooA https://t.c…
RT @FarmaMadridAP: (CMAJ) 5 aspectos a conocer sobre los inhibidores de PCSK9 (evolocumab y alirocumab) https://t.co/bvLBcEfooA https://t.c…
(CMAJ) 5 aspectos a conocer sobre los inhibidores de PCSK9 (evolocumab y alirocumab) https://t.co/bvLBcEfooA https://t.co/kTO2MKNpAJ
RT @Derek_Leong_RPh: Very happy to announce with @Pete_Wu that our "5 Things To Know About PCSK9 Inhibitors" article was published in @CMAJ…
RT @Derek_Leong_RPh: Very happy to announce with @Pete_Wu that our "5 Things To Know About PCSK9 Inhibitors" article was published in @CMAJ…
Great to see, and always fun to work with the one and only @Derek_Leong_RPh
RT @Derek_Leong_RPh: Very happy to announce with @Pete_Wu that our "5 Things To Know About PCSK9 Inhibitors" article was published in @CMAJ…
Economic evaluations of evolocumab and alirocumab incorporating data on clinical outcomes1,2 conclude that these medications are not cost-effective at current pricing, even with a $100 000 threshold quality-adjusted life-year cost.3–5 ... https://t.co/W9mp
Inibidores PCSK9 - revisão das recomendações e síntese da evidência Continuam a custar uma exorbitância... https://t.co/gDwOHU65jw #sinopse #evidentiamedica
RT @Derek_Leong_RPh: Very happy to announce with @Pete_Wu that our "5 Things To Know About PCSK9 Inhibitors" article was published in @CMAJ…
(CMAJ) Inhibidores de la PCSK9 https://t.co/36ChSuhSS2 Revisión
RT @Derek_Leong_RPh: Very happy to announce with @Pete_Wu that our "5 Things To Know About PCSK9 Inhibitors" article was published in @CMAJ…
Very happy to announce with @Pete_Wu that our "5 Things To Know About PCSK9 Inhibitors" article was published in @CMAJ today! https://t.co/k3TsQ0KC4i